Which has stronger earnings & valuation, ARGX or EXEL?

argenex has higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 12.74 $1.29B $26.04 33.22 Exelixis $2.32B 5.86 $782.57M $3.01 17.96

Is ARGX or EXEL more profitable?

Exelixis has a net margin of 35.33% compared to argenex's net margin of 32.19%. argenex's return on equity of 43.59% beat Exelixis' return on equity. Company Net Margins Return on Equity Return on Assets argenex 32.19% 43.59% 36.66% Exelixis 35.33% 42.17% 31.76%

Does the media refer more to ARGX or EXEL?

In the previous week, Exelixis had 28 more articles in the media than argenex. MarketBeat recorded 39 mentions for Exelixis and 11 mentions for argenex. argenex's average media sentiment score of 0.96 beat Exelixis' score of 0.43 indicating that argenex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 13 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor RVMD or EXEL?

In the previous week, Exelixis had 17 more articles in the media than Revolution Medicines. MarketBeat recorded 39 mentions for Exelixis and 22 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.82 beat Exelixis' score of 0.43 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 13 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Exelixis 13 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, NTRA or EXEL?

Exelixis has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Natera $2.31B 20.00 -$208.16M -$1.63 N/A Exelixis $2.32B 5.86 $782.57M $3.01 17.96

Is NTRA or EXEL more profitable?

Exelixis has a net margin of 35.33% compared to Natera's net margin of -7.11%. Exelixis' return on equity of 42.17% beat Natera's return on equity. Company Net Margins Return on Equity Return on Assets Natera -7.11% -11.82% -8.19% Exelixis 35.33% 42.17% 31.76%

Does the media refer more to NTRA or EXEL?

In the previous week, Exelixis had 2 more articles in the media than Natera. MarketBeat recorded 39 mentions for Exelixis and 37 mentions for Natera. Natera's average media sentiment score of 0.83 beat Exelixis' score of 0.43 indicating that Natera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natera 17 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Exelixis 13 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, EXEL or BIIB?

Biogen has higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.32B 5.86 $782.57M $3.01 17.96 Biogen $10.03B 3.06 $1.29B $5.65 36.80

Is EXEL or BIIB more profitable?

Exelixis has a net margin of 35.33% compared to Biogen's net margin of 8.32%. Exelixis' return on equity of 42.17% beat Biogen's return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.33% 42.17% 31.76% Biogen 8.32% 11.18% 6.88%

Does the media refer more to EXEL or BIIB?

In the previous week, Exelixis had 11 more articles in the media than Biogen. MarketBeat recorded 39 mentions for Exelixis and 28 mentions for Biogen. Biogen's average media sentiment score of 0.98 beat Exelixis' score of 0.43 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 13 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Biogen 18 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ALNY or EXEL?

In the previous week, Exelixis had 1 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 39 mentions for Exelixis and 38 mentions for Alnylam Pharmaceuticals. Exelixis' average media sentiment score of 0.43 beat Alnylam Pharmaceuticals' score of -0.08 indicating that Exelixis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 6 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 9 Negative mention(s) 0 Very Negative mention(s) Neutral Exelixis 13 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Exelixis (EXEL) Competitors

$54.07 +1.87 (+3.58%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$53.71 -0.36 (-0.67%)

As of 08/7/2026 07:34 PM Eastern

Compare

EXEL vs. ARGX, RVMD, NTRA, BIIB, and ALNY

Should you buy Exelixis stock or one of its competitors? MarketBeat compares Exelixis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Exelixis include argenex (ARGX), Revolution Medicines (RVMD), Natera (NTRA), Biogen (BIIB), and Alnylam Pharmaceuticals (ALNY). These companies are all part of the "biotechnology" industry.

How does Exelixis compare to argenex?

argenex (NASDAQ:ARGX) and Exelixis (NASDAQ:EXEL) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

In the previous week, Exelixis had 28 more articles in the media than argenex. MarketBeat recorded 39 mentions for Exelixis and 11 mentions for argenex. argenex's average media sentiment score of 0.96 beat Exelixis' score of 0.43 indicating that argenex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	13 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

argenex has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market.

Exelixis has a net margin of 35.33% compared to argenex's net margin of 32.19%. argenex's return on equity of 43.59% beat Exelixis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	32.19%	43.59%	36.66%
Exelixis	35.33%	42.17%	31.76%

argenex presently has a consensus price target of $1,056.89, suggesting a potential upside of 22.18%. Exelixis has a consensus price target of $49.79, suggesting a potential downside of 7.92%. Given argenex's stronger consensus rating and higher probable upside, analysts clearly believe argenex is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Exelixis	2 Sell rating(s)	10 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.26

argenex has higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	12.74	$1.29B	$26.04	33.22
Exelixis	$2.32B	5.86	$782.57M	$3.01	17.96

60.3% of argenex shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 2.4% of argenex shares are owned by insiders. Comparatively, 2.6% of Exelixis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

argenex beats Exelixis on 13 of the 17 factors compared between the two stocks.

How does Exelixis compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Exelixis (NASDAQ:EXEL) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

Exelixis has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,797.22	-$1.13B	-$7.07	N/A
Exelixis	$2.32B	5.86	$782.57M	$3.01	17.96

In the previous week, Exelixis had 17 more articles in the media than Revolution Medicines. MarketBeat recorded 39 mentions for Exelixis and 22 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.82 beat Exelixis' score of 0.43 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	13 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
Exelixis	13 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by insiders. Comparatively, 2.6% of Exelixis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Revolution Medicines has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market. Comparatively, Exelixis has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

Exelixis has a net margin of 35.33% compared to Revolution Medicines' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-102.61%	-70.72%
Exelixis	35.33%	42.17%	31.76%

Revolution Medicines currently has a consensus price target of $153.05, suggesting a potential downside of 25.39%. Exelixis has a consensus price target of $49.79, suggesting a potential downside of 7.92%. Given Exelixis' higher probable upside, analysts plainly believe Exelixis is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95
Exelixis	2 Sell rating(s)	10 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.26

Summary

Exelixis beats Revolution Medicines on 9 of the 17 factors compared between the two stocks.

How does Exelixis compare to Natera?

Natera (NASDAQ:NTRA) and Exelixis (NASDAQ:EXEL) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

Exelixis has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31B	20.00	-$208.16M	-$1.63	N/A
Exelixis	$2.32B	5.86	$782.57M	$3.01	17.96

Natera currently has a consensus target price of $299.65, indicating a potential downside of 6.97%. Exelixis has a consensus target price of $49.79, indicating a potential downside of 7.92%. Given Natera's stronger consensus rating and higher probable upside, equities research analysts clearly believe Natera is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	2 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.77
Exelixis	2 Sell rating(s)	10 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.26

99.9% of Natera shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 5.1% of Natera shares are owned by insiders. Comparatively, 2.6% of Exelixis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Exelixis had 2 more articles in the media than Natera. MarketBeat recorded 39 mentions for Exelixis and 37 mentions for Natera. Natera's average media sentiment score of 0.83 beat Exelixis' score of 0.43 indicating that Natera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natera	17 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Exelixis	13 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Natera has a beta of 1.51, meaning that its stock price is 51% more volatile than the broader market. Comparatively, Exelixis has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market.

Exelixis has a net margin of 35.33% compared to Natera's net margin of -7.11%. Exelixis' return on equity of 42.17% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-7.11%	-11.82%	-8.19%
Exelixis	35.33%	42.17%	31.76%

Summary

Natera beats Exelixis on 9 of the 17 factors compared between the two stocks.

How does Exelixis compare to Biogen?

Exelixis (NASDAQ:EXEL) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

85.3% of Exelixis shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 2.6% of Exelixis shares are held by company insiders. Comparatively, 0.3% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Exelixis had 11 more articles in the media than Biogen. MarketBeat recorded 39 mentions for Exelixis and 28 mentions for Biogen. Biogen's average media sentiment score of 0.98 beat Exelixis' score of 0.43 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	13 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Biogen	18 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market.

Biogen has higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	5.86	$782.57M	$3.01	17.96
Biogen	$10.03B	3.06	$1.29B	$5.65	36.80

Exelixis currently has a consensus target price of $49.79, suggesting a potential downside of 7.92%. Biogen has a consensus target price of $224.61, suggesting a potential upside of 8.02%. Given Biogen's stronger consensus rating and higher probable upside, analysts clearly believe Biogen is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	10 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.26
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56

Exelixis has a net margin of 35.33% compared to Biogen's net margin of 8.32%. Exelixis' return on equity of 42.17% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Biogen	8.32%	11.18%	6.88%

Summary

Biogen beats Exelixis on 10 of the 17 factors compared between the two stocks.

How does Exelixis compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Exelixis (NASDAQ:EXEL) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 2.6% of Exelixis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Exelixis has a net margin of 35.33% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Exelixis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Exelixis	35.33%	42.17%	31.76%

Alnylam Pharmaceuticals currently has a consensus price target of $396.72, indicating a potential upside of 80.98%. Exelixis has a consensus price target of $49.79, indicating a potential downside of 7.92%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.92
Exelixis	2 Sell rating(s)	10 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.26

In the previous week, Exelixis had 1 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 39 mentions for Exelixis and 38 mentions for Alnylam Pharmaceuticals. Exelixis' average media sentiment score of 0.43 beat Alnylam Pharmaceuticals' score of -0.08 indicating that Exelixis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	6 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	9 Negative mention(s)	0 Very Negative mention(s)	Neutral
Exelixis	13 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Alnylam Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

Exelixis has lower revenue, but higher earnings than Alnylam Pharmaceuticals. Exelixis is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$4.80B	6.11	$313.75M	$5.38	40.74
Exelixis	$2.32B	5.86	$782.57M	$3.01	17.96

Summary

Alnylam Pharmaceuticals beats Exelixis on 10 of the 17 factors compared between the two stocks.

Get Exelixis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EXEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EXEL vs. The Competition

Export

Metric	Exelixis	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$13.12B	$3.62B	$6.94B	$12.86B
Dividend Yield	N/A	3.77%	2.59%	10.09%
P/E Ratio	17.00	8.94	270.26	25.05
Price / Sales	5.86	1,271.39	601.25	100.65
Price / Cash	17.24	98.58	71.46	49.72
Price / Book	7.37	18.10	13.25	6.21
Net Income	$782.57M	-$13.22M	$3.45B	$342.45M
7 Day Performance	1.96%	6.27%	4.63%	4.41%
1 Month Performance	-3.64%	-2.67%	-0.81%	-0.28%
1 Year Performance	43.35%	61.22%	77.73%	22.60%

Exelixis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EXEL Exelixis	2.452 of 5 stars	$54.07 +3.6%	$49.79 -7.9%	+44.6%	$13.12B	$2.32B	17.00	1,077	Trending News Earnings Report Analyst Forecast Analyst Revision
ARGX argenex	4.5015 of 5 stars	$844.50 +1.7%	$1,056.89 +25.1%	+28.7%	$52.83B	$4.25B	32.43	1,863	Analyst Forecast
RVMD Revolution Medicines	1.7655 of 5 stars	$193.46 +6.0%	$144.67 -25.2%	+487.0%	$41.13B	$11.58M	N/A	250	Earnings Report Analyst Forecast
NTRA Natera	2.9685 of 5 stars	$275.19 +1.8%	$267.83 -2.7%	+128.3%	$39.41B	$2.50B	N/A	6,140	Trending News Earnings Report Analyst Forecast Insider Trade Gap Up
BIIB Biogen	3.8937 of 5 stars	$208.45 +3.3%	$224.61 +7.8%	+62.8%	$30.80B	$9.89B	36.89	7,500	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EXEL) was last updated on 8/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exelixis (EXEL) Competitors